Monoamine oxidase type B (MAO-B) inhibitors are a class of drugs widely used in the treatment of Parkinson's disease that work by blocking the enzyme responsible for the breakdown of dopamine in the brain. Three MAO-B inhibitors are currently approved for clinical use: selegiline (first generation), rasagiline (second generation), and safinamide (third generation). Among all classes of anti-parkinsonian drugs, MAO-B inhibitors have demonstrated the greatest neuroprotective potential in preclinical studies, through mechanisms including reduction of oxidative stress, inhibition of dopamine metabolism, and stimulation of neurotrophic factor release.
Dopamine released from nigrostriatal terminals in the striatum is metabolized through two main pathways:
- MAO-B pathway: Dopamine → 3,4-dihydroxyphenylacetaldehyde (DOPAL) → 3,4-dihydroxyphenylacetic acid (DOPAC)
- COMT pathway: Dopamine → 3-methoxytyramine (3-MT)
MAO-B catalyzes the first step in the primary degradation pathway. This reaction generates hydrogen peroxide (H₂O₂) as a byproduct, which contributes to oxidative stress and nigrostriatal neurodegeneration.
MAO-B is located predominantly on the outer mitochondrial membrane of astrocytes and serotonergic neurons in the brain. Its expression increases with age and in neurodegenerative conditions, making it both a therapeutic target and a potential contributor to disease progression.
flowchart TD
A["Parkinsons Disease"] --> B["Loss of Dopaminergic Neurons in SNpc"]
B --> C["Reduced Dopamine Production"]
C --> D["Motor Symptoms of PD"]
E["MAO-B Inhibitors"] --> F["Irreversible Inhibition of MAO-B Enzyme"]
F --> G["Reduced Dopamine Degradation"]
G --> H["Increased Synaptic Dopamine Levels"]
H --> I["Improved Motor Function"]
D -.->|Treatment| I
J["MPTP Neurotoxicity"] --> K["MAO-B Activates MPTP to MPP+"]
K --> L["Selective Dopaminergic Toxicity"]
L -.->|"Inhibition"| F
¶ Landmark Clinical Trials
The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial was the first large multicenter study examining early selegiline treatment in Parkinson's disease:
- Design: 800 patients with early, untreated PD randomized to selegiline (10 mg/day), tocopherol (vitamin E, 2000 IU/day), both, or placebo
- Primary endpoint: Time to requiring levodopa therapy
- Results: Selegiline delayed the need for levodopa by approximately 9 months. Tocopherol showed no benefit
- Controversy: The observed benefit was debated as being purely symptomatic rather than neuroprotective, as the drug washout period (2 months) was shorter than the time required for full recovery of MAO-B activity after irreversible inhibition
The Attenuation of Disease Progression with Azilect Given Once-daily (ADAGIO) trial tested whether rasagiline had disease-modifying effects using a delayed-start design:
- Design: 1,176 patients with early PD randomized to rasagiline 1 mg/day or 2 mg/day (early start) vs. placebo for 36 weeks then rasagiline (delayed start) for 36 weeks
- Results: The 1 mg/day group met all three hierarchical endpoints, consistent with a disease-modifying effect. The 2 mg/day group did not, creating an unresolved dose-response paradox
- Significance: First trial to use delayed-start design in PD; results remain debated
- Design: 549 mid-to-late PD patients on levodopa randomized to safinamide (50–100 mg/day) or placebo for 24 weeks
- Results: Safinamide significantly increased daily "on" time by 1.42 hours vs. 0.57 hours for placebo, decreased "off" time, and improved UPDRS motor scores
- Long-term extension (MOTION): Sustained benefits observed over 2 years
MAO-B inhibitors have consistently demonstrated the greatest neuroprotective potential among all classes of anti-parkinsonian drugs:
- Reduction of oxidative stress: By inhibiting MAO-B, these drugs decrease the production of H₂O₂ generated during dopamine metabolism
- Anti-apoptotic effects: Propargylamine-containing compounds (selegiline, rasagiline) upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and downregulate pro-apoptotic factors (Bad, Bax, caspases)
- Neurotrophic factor induction: Stimulate production and release of GDNF and BDNF, which support dopaminergic neuron survival
- Anti-inflammatory effects: Reduce microglial activation and pro-inflammatory cytokine release in the striatum
- Glutamate modulation (safinamide): Inhibits excessive glutamate release, counteracting excitotoxicity in the basal ganglia motor circuit
Recent systematic reviews have highlighted MAO-B inhibitor benefits beyond motor symptoms:
- Quality of life: Rasagiline and safinamide significantly improved quality of life measures (PDQ-39) compared to placebo
- Depression: Safinamide demonstrated improvements in depression scores, potentially through its dual dopaminergic/glutamatergic mechanism
- Pain: Safinamide reduced musculoskeletal and neuropathic pain in PD patients
- Fatigue: Both rasagiline and safinamide showed benefits for fatigue
- Sleep: Mixed results; selegiline may worsen insomnia due to amphetamine metabolites, while rasagiline and safinamide have neutral to beneficial effects
- Cognition: Some evidence for cognitive benefit, particularly with rasagiline, possibly through noradrenergic and serotonergic effects
¶ Safety and Drug Interactions
- Selegiline: Insomnia, nausea, orthostatic hypotension, confusion, hallucinations (especially in elderly)
- Rasagiline: Headache, arthralgia, dyspepsia, dizziness
- Safinamide: Dyskinesia (when added to levodopa), nausea, falls, insomnia
- Tyramine-containing foods: At therapeutic doses, MAO-B inhibitors have minimal risk of the "cheese effect" (hypertensive crisis), unlike non-selective MAO inhibitors. Risk increases only at supratherapeutic doses that inhibit MAO-A.
MAO-B inhibitors are being investigated for other neurodegenerative conditions:
- Alzheimer's disease: MAO-B activity is elevated in astrocytes surrounding amyloid plaques; selegiline and rasagiline have shown modest cognitive benefits in AD trials. Novel MAO-B inhibitors that also target amyloid are in development
- ALS: Rasagiline demonstrated a potential disease-modifying effect in ALS clinical trials, possibly through anti-apoptotic mechanisms
- Huntington's disease: Preclinical evidence suggests neuroprotective effects in striatal neurons
- Depression: Selegiline transdermal patch (Emsam) is FDA-approved for major depressive disorder
- Traumatic brain injury: Neuroprotective potential under investigation